Secukinumab demonstrates significant improvement of disease activity and health-related quality of life at 1 year in Canadian psoriasis patients in a real world setting
This study aims to assess the real-world effectiveness of SEC in Canadian patient s with Pso, analyzing patient demographics, treatment patterns, and impact on disease/QoL at 1 year.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
More News: Academies | Ankylosing Spondylitis | Arthritis | Canada Health | Dermatology | Psoriasis | Psoriatic Arthritis | Rheumatology | Skin | Study